355805-96-8

Basic information

• Product Name: Rosuvastatin MethanaMine Salt
• Synonyms: Rosuvastatin MethanaMine Salt;Intermediates of Rosuvastatin Calcium R-3
• CAS NO: 355805-96-8
• Molecular Formula: CH₅N*C₂₂H₂₈FN₃O₆S
• Molecular Weight: 512.59500
• Mol File: 355805-96-8.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Rosuvastatin MethanaMine Salt(CAS DataBase Reference)
• NIST Chemistry Reference: Rosuvastatin MethanaMine Salt(355805-96-8)
• EPA Substance Registry System: Rosuvastatin MethanaMine Salt(355805-96-8)

Safety Data

• Hazardous Substances Data: 355805-96-8(Hazardous Substances Data)

Usage

General Description

Rosuvastatin Methanamine Salt is a chemical compound derived from rosuvastatin, a medication used to lower cholesterol levels. Rosuvastatin Methanamine Salt is formed by reacting rosuvastatin with methanamine, resulting in the formation of a salt. Rosuvastatin works by inhibiting the enzyme HMG-CoA reductase, which is responsible for the production of cholesterol in the body. The methanamine salt form of rosuvastatin may have improved stability and solubility compared to the original compound, making it potentially more effective for use in medication formulations. The salt form of rosuvastatin is likely to be used in the production of pharmaceutical products for the treatment of high cholesterol and other related conditions.

Upstream product

• 74-89-5 methylamine 
• 287714-41-4 rosuvastatin 
• 289042-12-2 2-[(4R,6S)-6-[(E)-2-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonamido)-6-(isopropyl)pyrimidin-5-yl]vinyl]-2,2-dimethyl-1,3-dioxan-4-yl]acetic acid tert butyl ester 
• 124752-23-4 tert-butyl 2-[(4R,6S)-6-formyl-2,2-dimethyl-1,3-dioxan-4-yl]acetate 
• 1257341-56-2 2-methyl-1-phenylpropan-2-yl 2-((4R,6S)-6-((E)-2-(4-(4-fluorophenyl)-6-isopronyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 
• 1257341-59-5 (3R,5S)-2-methyl-1-phenylpropan-2-yl 6-chloro-3,5-dihydroxy-hexanoate 
• 1257341-57-3 2-methyl-1-phenylpropan-2-yl (S)-6-chloro-5-hydroxy-3-oxohexanoate 
• 1257341-69-7 2-methyl-1-phenylpropan-2-yl 2-((4R,6S)-2,2-dimethyl-6-((1-phenyl-1H-tetrazol-5-ylsulfonyl)methyl)-1,3-dioxan-4-yl)acetate 
• 1257341-65-3 2-methyl-1-phenylpropan-2-yl 2-((4R,6S)-2,2-dimethyl-6-((1-phenyl-1H-tetrazol-5-ylthio)methyl)-1,3-dioxan-4-yl)acetate 
• 1257341-61-9 2-methyl-1-phenylpropan-2-yl 2-((4R,6S)-6-(chloromethyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate 

Downstream Products

• 287714-41-4 rosuvastatin 
• 355806-08-5 lithium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid 
• 355806-06-3 ammonium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxyhept-6-enoic acid 
• 503610-43-3 Rosuvastatin lactone 

Relevant articles and documents

Purification method of rosuvastatin calcium key intermediate

The invention provides a purification method of a rosuvastatin calcium intermediate. The rosuvastatin calcium intermediate has a structure of a compound (4). The purification method comprises following steps: adding an alcohol solvent and water into a crude product containing the compound (4), then adding an ether solvent, cooling, and crystallizing to obtain the compound (4). The structure of thecompound (4) is represented in the description. The provided purification method has the advantages of simple operation, high yield, and good selectivity, can obtain high purity rosuvastatin calciumkey intermediate, which is used to prepare high quality rosuvastatin calcium, and improves the drug quality.

NOVEL METHOD FOR PREPARING ROSUVASTATIN, INTERMEDIATE COMPOUNDS USEFUL FOR PREPARING SAME, AND METHOD FOR PREPARING SAME

The present invention relates to novel intermediate compounds used in preparing Rosuvastatin or the pharmaceutically acceptable salts thereof, to a method for preparing same, and to a method for preparing Rosuvastatin or the pharmaceutically acceptable salts thereof from the intermediates. The preparation method of the present invention has the effect of providing Rosuvastatin hemi-calcium salts with an excellent yield rate.

Process for the preparation of pyrimidine derivatives

An improved process for the preparation of pyrimidine derivatives is provided comprising reacting a Wittig reagent of the general formula wherein R is an alkyl of from 1 to 10 carbon atoms, aryl or arylalkyl, R1 is a substituted or unsubstituted hydrocarbon group, R2 and R3 are the same or different and are hydrogen or a substituted or unsubstituted hydrocarbon group; Z is sulfur, oxygen, sulfonyl, or imino which may be substituted by formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, amino substituted by sulfonyl or alkylsulfonyl, and sulfonyl substituted by alkyl, amino or alkylamino and X is a halogen; with an aldehyde of the general formula wherein R4 is hydrogen, a lower alkyl or a cation capable of forming a non-toxic pharmaceutically acceptable salt and each R5 are the same or different and are hydrogen or a hydrolyzable protecting group, or each R5, together with the oxygen atom to which each is bonded, form a hydrolyzable cyclic protecting group, or each R5 is bonded to the same substituent which is bonded to each oxygen atom to form a hydrolyzable protecting group; in the presence of a base.